

TNF alpha antibody

Cat. No. GTX31193

Host	Goat
Clonality	Polyclonal
Applications	WB, IHC-Fr, ELISA, Neutralizing/Inhibition
Reactivity	Mouse

Package 100 μg

Applications

Application Note

We recommend the following starting dilutions: For WB: Use at a concentration of 0.1-0.2 μ g/ml. For ELISA: Use at a concentration of 0.5-2.0 μ g/ml. For IHC-Fr: Use at a concentration of 1.0 μ g/ml. For Neutralization: one-half maximal inhibition [ND50] of the biological activity of Mouse TNF- α (0.25 ng/ml), a concentration of 0.05-0.08 μ g/ml of this antibody is required. Optimal dilutions should be determined experimentally by the end user.

Calculated MW 26 kDa. (Note)

Properties	
Form	Liquid
Buffer	PBS pH7.2
Preservative	No preservative
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
Concentration	Batch dependent (Please refer to the vial label for the specific concentration.)
Immunogen	E.coli derived Recombinant Murine TNF- α
Purification	Affinity Purified
Conjugation	Unconjugated
Note	For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
	Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.




For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 07 / 15 Page 1 of 2

€ 886-3-6208988 📻 886-3-6208989 🐷 infoasia@genetex.com



DATA IMAGES



GTX31193 IHC-Fr Image

IHC analysis of colchicine injected mouse brain (hippocampus CA1 region) tissue using TNF alpha antibody at a concentration of 1.0 μ g/ml. This was followed by a peroxidase conjugated secondary antibody and then a fluorescein Tyramide Signal Amplification (TSA) reagent.



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 07 / 15 Page 2 of 2